Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melatonin + Hyaluronic acid is a combination product comprising melatonin, a naturally occurring hormone, and hyaluronic acid, a glycosaminoglycan. Melatonin primarily functions as an agonist for MT1 and MT2 G protein-coupled receptors, regulating circadian rhythms and promoting sleep. It also exhibits significant antioxidant and anti-inflammatory properties. Hyaluronic acid is a key component of the extracellular matrix, known for its ability to attract and retain water, providing lubrication, cushioning, and structural support. It also plays roles in cell migration, proliferation, and tissue repair, often interacting with the CD44 receptor. The combination is being investigated for synergistic effects, particularly in topical applications for conditions such as periodontal disease and bone healing, leveraging melatonin's antioxidant and anti-inflammatory actions with hyaluronic acid's tissue-supporting and regenerative capabilities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Melatonin + Hyaluronic acid.